Press "Enter" to skip to content

New efficacy rate announced against Delta variant of Pfizer-BioNTech vaccine – Health News

The new study, published in the famous medical journal New England Journal of Medicine, investigated the effects of Pfizer-BioNTech and AstraZeneca corona virus vaccines on the Delta variant, which has already become the dominant strain in the world.

In the report released yesterday, it was reported that two doses of the Pfizer-BioNTech vaccine were 88 percent effective in preventing symptomatic cases caused by the Delta variant.

In the study, it was reported that two doses of AstraZeneca vaccine were 67 percent effective against the Delta variant.


In the published report, it was reported that the effectiveness of the vaccines was almost the same as that against the Alpha variant, which had become the dominant strain in the world, and the importance of having two doses of vaccine was emphasized.

While officials say the vaccines are highly effective against the Delta variant, which is currently the dominant strain worldwide, the study reiterated that one dose of the vaccines is not enough for high protection.


The report found that a dose of Pfizer-BioNTech vaccine against the Delta variant was 36 percent effective, and a dose of AstraZeneca vaccine was about 30 percent effective.

“Only modest differences in vaccine efficacy were noted in the Delta variant compared to the Alpha variant after receiving two doses of the vaccine,” the Public Health England researchers said in the study.

In a previous study in Israel, it was announced that two doses of Pfizer-BioNTech vaccine were 70 percent effective against the Delta variant.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *